Monday, February 7, 2000
WASHINGTON - The outcry over informed consent following the
death of a clinical trial volunteer at the University of Pennsylvania's Institute
for Human Gene Therapy (IHGT) could have widespread impact on biomedical research
extending well beyond gene therapy.
Congress, regulatory agencies, and ethics watchdogs have been
prompted to launch or accelerate investigations into the adequacy of patient
protections in the wake of allegations that IHGT investigators violated informed